RNS Number : 6581K
N4 Pharma PLC
23 April 2020

23 April 2020

N4 Pharma plc
("**N4 Pharma**", the "**Company**" or the "**Group**")

Result of Annual General Meeting

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. The results of the proxy voting for the AGM are set out below.

	Resolution	*Total votes For*[1]	*% of votes cast*[2]	*Total Votes Against*	*% of votes cast*[2]	*Total Votes Cast*[3]	*% of issued share capital*	*Votes Withheld*[4]
1	To receive the annual report and audited accounts for the year ended 31 December 2019	30,624,816	100.00	-	0.00	30,625,416	30.18	200
2	To re-elect Nigel Theobald as a director of the Company	30,620,596	100.00	200	0.00	30,621,396	30.18	4,200
3	To re-elect David Templeton as a director of the Company	30,620,596	100.00	200	0.00	30,621,396	30.18	4,200
4	To re-appoint Saffery Champness LLP as auditor to the company and authorise the directors to determine their remuneration	30,624,796	100.00	200	0.00	30,625,596	30.18	200
5	To authorise the directors to allot shares	30,620,396	100.00	200	0.00	30,621,396	30.18	4,200
6	To disapply pre-emption rights*	30,618,996	100.00	200	0.00	30,620,596	30.18	5,000

7	To adopt new Articles of Association of the Company*	30,620,396	100.00	200	0.00	30,625,396	30.18	200

Notes:

* Proposed as special resolutions

1. Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution
2. Percentage of votes cast excludes Votes Withheld
3. Total Votes Cast do not include withheld votes
4. Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution

Enquiries:

N4 Pharma Plc
Nigel Theobald, CEO — Via Scott PR

Allenby Capital Limited — Tel: +44(0)203 328 5656
James Reeve/Asha Chotai

Scott PR — Tel: +44(0)1477 539 539
Georgia Smith

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGGCGDSCUDDGGX